NMT Group PLC
14 October 2002
14 October 2002
NMT Group PLC
Interim Update
NMT Group, the manufacturer of retractable devices to prevent needlestick
injury, announces today:-
Key points
• Signing of a Global Supply Agreement with Roche for supply of 1cc and
3cc retractable safety syringes. The syringes will be packaged alongside Roche's
Fuzeon(R), a revolutionary drug for the treatment of HIV.
• Livingston manufacturing facility recommences production of 1st
Generation syringe product as a result of Roche contract.
• Discussions with potential partners for the licensing of 2nd
Generation syringe technology are ongoing.
• NMT to focus commercial and product development efforts in
pharmaceutical sector
• Strong financial position - cash balance at 30 September 2002 £17m.
Commenting on the results, Roy Smith, Chief Executive Officer, said:
'I am delighted that we have reached agreement with Roche, one of the world's
leading pharmaceutical companies, for the supply of our retractable syringes.
This agreement represents a significant milestone in the history of NMT, and
should create a platform on which we can achieve further commercial success. I
am equally pleased that the result of this contract will allow recommencement of
production at our Livingston facility and our staff, who deserve this success,
can now focus on increased output over a sustainable period. On the strength of
this Agreement we will increase our commercial and product development focus
within the pharmaceutical sector where, I believe, our current intellectual
property can create real value.
'I also remain encouraged at the level of interest which we are receiving from
large medical device companies in the licensing of our second generation syringe
technology for the Acute Hospital market, particularly in the US, where
discussions with potential partners are ongoing.'
Enquiries:
NMT Group PLC
Roy Smith, Chief Executive Officer Tel: 01590 687 901
Gerard Cassels, Finance Director Tel: 01506 445 004
Financial Dynamics Tel: 0207 831 3113
Fiona Noblet
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.